Patent ID: 6534501
Filing Date: 2003-03-18
Classification: A61K

Abstract:
A method for allosterically modifying pyruvate kinase in a patient, comprising the step of providing a patient in need thereof with a sufficient quantity of a compound which inhibits pyruvate kinase activity, wherein said compound is selected from the group consisting of[3-Butyl-3-(10-chloro-anthracen-9-ylmethyl)-ureido]-acetic acid ethyl ester; 2-[(9-Methyl-phenazine-1-carbonyl)-amino]-benzoic acid; 2-(4-Chloro-phenylamino)-benzo[d][1,3]oxazin-4-one; 3-(2-{1-(3-Chlorophenyl)-1(3-hydroxyphenyl)-ureido]-ethyl}-4-oxo-4H-quinazolin-3-yl)-propionic acid; 2-(9-Ethyl-9H-carbazol-3-ylvinylideneamino)-1-(4-nitrobenzoate); Chloroacetic acid 3-[2-(2-ethyl-4-oxo-4H-quinazolin-3-yl)ethyl]-indol-lylmethylester; 3-Benzylamino-5-(4-chlorophenyl)-4H-1&lgr;4-thiophene-2-carboxylic acid methyl ester; 5-[2-(3,5-Dichlorobenzoylamino)-4-methoxycarbonyl-phenoxy]-isophtahlic acid dimethyl ester; 5-[2-(3-Cyclohexyl-ureido)-4-methoxycarbonyl-phenoxy]-isophtahlic acid dimethyl ester; 5-{4-Methoxycarbonyl-2-[3-(3-trifluoromethylphenylureido]-phenoxy}-isophthalic acid dimethyl ester; 4-[3,5-Bistrifluoromethylphenyl)-1-(4-methoxybenzyl)-ureidomethyl]-piperidine-1-carboxylic acid ter-butyl ester; 2-{3-[1-(2-Chloro-2-phenylacetyl)-piperidn-4-ylmethylureido}-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ethyl ester; and pharmaceutically acceptable salts thereof.